Moderna-Merck mRNA Vaccine with Keytruda Cuts Skin Cancer Recurrence by 44%

April 19, 2023

(UPI) – The risk of recurrence of deadly skin cancer was reduced by nearly half when patients were treated with an mRNA vaccine developed by Moderna and Merck Co. and the immunotherapy Keytruda drug, according to a new study. The findings, published Sunday, show that 44% of patients who received the combination therapy reduced the risk of recurrence compared to those who only received the Merck-developed Keytruda.  (Read More)